COVID-19 Pharmacovigilance Flexibilities 'Must Remain' In Non-EU Markets
Companies Are Concerned Positive Changes May Be Rolled Back After Pandemic Ends
An EU industry group is scrutinizing the several ‘impactful’ changes made by countries to their pharmacovigilance processes amid the ongoing COVID-19 pandemic. The group is hoping these changes can help its ongoing efforts to create ‘right size’ systems where there is a need to further develop infrastructure for pharmacovigilance.
You may also be interested in...
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a newly-created regulatory oversight group has identified several topics requiring further scientific discussion.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
The European Commission has launched the process for reshaping and addressing the long-standing weakness in the EU’s pharmaceutical legislation. It has listed in a roadmap the issues it wants to address as it considers policy options for reforms.